title: Long-term infliximab treatment for Behçet's disease.
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Takamoto
authors.forename: Toshikatsu
authors.initials: T
authors.lastname: Kaburaki
authors.forename: Jiro
authors.initials: J
authors.lastname: Numaga
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Fujino
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Kawashima
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha; D014792:Visual Acuity; D014822:Vitreous Body / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab